SOLICITATION NOTICE
99 -- 99-Mouse Unigene 1
- Notice Date
- 8/26/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20091-NQ
- Response Due
- 9/11/2002
- Point of Contact
- Cynthia Brown, Purchasing Agent, Phone (301) 496-8608, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
cb106x@nih.gov, cr214i@nih.gov
- Small Business Set-Aside
- Total Small Business
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR) plans to enter into a sole source contract with Incyte Genomics, In., 3160 Porter Drive, Palo Alto, CA 94304, to acquire one set of Mouse Unigene I Easy to Spot PCR Products. Incyte Genomics, Inc., is the only provider of this unique set. The Center for Cancer Research maintains a state-of-the-art facility for the production of gene microarrays. The microarrays allow researcher to study simultaneously by differential expression of large numbers of cancer genes in normal and diseased or treated cells. The CCR Microarray Facility uses modern lab automation and robotic methods to "print" these arrays by spotting small volumes of prepared cDNA clones (PCR products) at specific location on specially prepared glass slides. (PCR products of cDNA clones from multiple thousands of genes can localized to small glass slide. The composition of the PCR sets and quality controls used in their manufacture are critically important for the continuation of existing experimental protocols and standards. The NCI/CCR Microarray facility has ongoing projects utilizing Incyte products previously (263-MQ-211701), having produced thousands of microarrays which are in use by intramural invesitgators and the NIH MouseModels of Human Disease Consortium. An important aspect is the clones are not full-length copies of the genes of interest, but are biased towards the 3' end of the gene. In practical terms, this means that clone form the same genes, but generated from other vendors, will have a different composition. It is critical for experimental continuity and reproducibility that the NCI/CCR continue to acquire from this source. Incyte Genomics Inc., is the only source known to the government that can meet the required specifications. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. Capability statements and any other furnished information must be in writing and must contain sufficient matieral to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 1:30 PM EST (local Washington, D.C. time) on September 11, 2002. This action is pursuant to 41 USC 253(1) and under the authority of FAR 6.302-1. If you have any questions, pleae contact Cynthia Brown, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed requirement based on respones to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a compeitive procurement. No collect calls will be accpeted. NAICS Code: 325413.
- Record
- SN00149879-W 20020828/020826213227 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |